|
ABRAXANE® (nanoparticle, albumin-bound [nab] paclitaxel) Reimbursement/ Coverage
 ABRAXANE® (nanoparticle, albumin-bound [nab] paclitaxel) DIN 02281066
ABRAXANE® Patient Assistance Program (APAP) : 1-888-525-5959
The ABRAXANE® Patient Assistance Program will research and investigate private reimbursement options for patients. For oncologists who wish to print off a Patient Enrollment Form, please click here.
ABRAXANE® is an eligible benefit through some private insurance plans, and by some provincial drug programs and federal plans. ABRAXANE® is currently being reviewed for funding in other provinces and territories.The sidebar menu allows you to access specific information on coverage of ABRAXANE® by private insurance plans, the individual provincial drug benefit/ provincial cancer agency programs and through the federal drug plans. Information includes coverage/ reimbursement criteria, guidelines, special authorization requirements, Claims instructions and other resources. Click on the plan or program name to access.
Indication
ABRAXANE® for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound [nab] paclitaxel) is indicated for:- the treatment of metastatic breast cancer.
Contraindications1:
Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container.
ABRAXANE® for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound [nab] paclitaxel) should not be used in patients who have baseline neutrophil counts of <1,500 cells/mm3.1
Note: An albumin form of paclitaxel may substantially affect a drug's functional properties relative to those of drug in solution. Do not substitute with or for other paclitaxel formulations. In the treatment of metastatic breast cancer ABRAXANE® has been evaluated as a single agent only.
1Reference: ABRAXANE® Product Monograph
Resources for Healthcare Professionals and Patients
Cancer Care Ontario
Nanoparticle, Albumin Bound (nab)-PACLITAXEL Chemotherapy Regimen
BC Cancer Agency
Chemotherapy Protocol,
BRAVABR: Palliative Therapy for Metastatic Breast Cancer using nanoparticle, albumin-bound (nab)-Paclitaxel (Abraxane®)
Alberta Cancer Board
OPTIMAL USE OF TAXANES IN METASTATIC BREAST CANCER
Willow Web Site
Wellspring Web Site
Canadian Breast Cancer Network
Cancer Advocacy Coalition Canada Web Site
ABRAXANE® Product Monograph
®Trademark of Abraxis BioScience Canada, Inc.
|
